A Phase II Study to Assess the Efficacy, Safety and Tolerability of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapeutic Regimen

Trial Profile

A Phase II Study to Assess the Efficacy, Safety and Tolerability of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapeutic Regimen

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Risperidone (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors ValiRx
  • Most Recent Events

    • 27 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 14 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 13 Sep 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top